One of the biggest breakthroughs in the treatment of psoriasis and psoriatic arthritis was the introduction of biologic agents (like TNF-α inhibitors, inhibitors of the IL-17 pathway, inhibitors of IL-23, and related cytokines) and Janus kinase (JAK) inhibitors. This evidence concerns the gene IL17A and psoriasis.